Search

Broth-microdilution was performed, as per clinical and laboratory standards institute (CLSI) standards,[7] to test the I in vitro i activity of LZD, SZD, and DZD against clinical isolates of I Mycobacterium abscessus i ( I n i = 45), I Mycobacterium massiliense i ( I n i = 29), I Mycobacterium kansasii i ( I n i = 28), I Mycobacterium avium i ( I n i = 13), and I Mycobacterium intracellulare i ( I n i = 16) characterized by matrix-assisted laser desorption-ionization time-of-flight. SZD showed the strongest antimicrobial activity against the slowly growing mycobacterium, followed by DZD, whereas SZD and DZD showed similar values against the rapidly growing mycobacterium. B Dear Editor: b The prevalence of nontuberculous mycobacterial pulmonary disease is increasing worldwide.[1],[2] However, the acquired resistance renders treatment highly challenging.[3] The oxazolidinones exhibit good activity against Gram-positive bacteria.[4] Linezolid (LZD), the first licensed oxazolidinone, exhibits excellent antibacterial activities against nontuberculous mycobacteria (NTM) infections.[4] Sutezolid (SZD) exhibited superior efficacy against I Mycobacterium tuberculosis i .[2],[4],[6] Delpazolid (DZD) improved antibacterial activity and safety against Gram-positive pathogen.[[4], [6]] However, comparison of the oxazolidinone derivatives for NTM isolates are limited. [Extracted from the article]